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Immunotherapeutics for lung cancer include peptide vaccine therapy, immune cell therapy and immune checkpoint inhibitors. The recent development of immune checkpoint inhibitors has been remarkable. Nivolumab, a human IgG4 PD-1 monoclonal antibody immune checkpoint inhibitor, has demonstrated a clinically-meaningful survival benefit compared with the current standard treatment in patients with advanced previously-treated nonsmall cell lung cancer (NSCLC). However, it is necessary to pay attention to immune-mediated adverse events at the time of treatment. It is essential to immediately establish predictive biomarkers for anti-cancer drug selection in NSCLC patients. 
